20 results
8-K
DRMA
Dermata Therapeutics Inc
12 Jan 24
Submission of Matters to a Vote of Security Holders
4:06pm
Inducement Letter, dated as of November 16, 2023, by and between the Company and the investor named on the signatory page thereto, and the Engagement
8-K
EX-4.2
qzqs2qs1
17 Nov 23
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
4:06pm
8-K
u1xrss
17 Nov 23
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
4:06pm
8-K
0abhf1
9 Nov 23
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:08pm
DEFA14A
kba8pe241zebiu9
12 Jul 23
Additional proxy soliciting materials
9:02am
424B5
6kwa5q4 hbbbw4h
25 May 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-4.3
y23b31glci l28sjt
24 May 23
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
5:13pm
8-K
EX-10.3
z96k yw33yb5
25 Apr 22
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
4:45pm
424B3
29sd1cba2k eu7h0a
1 Sep 21
Prospectus supplement
4:56pm
8-K
EX-10.1
3jcrfgwfhcu3mt09f
1 Sep 21
Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer
4:50pm
S-1
EX-10.1
76bhjt6
10 Jun 21
IPO registration
5:11pm
- Prev
- 1
- Next